GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EV-to-EBITDA

I-MAB (IMAB) EV-to-EBITDA : -0.24 (As of Jul. 07, 2025)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, I-MAB's enterprise value is $10.63 Mil. I-MAB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-44.78 Mil. Therefore, I-MAB's EV-to-EBITDA for today is -0.24.

The historical rank and industry rank for I-MAB's EV-to-EBITDA or its related term are showing as below:

IMAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.83   Med: 1.4   Max: 47.7
Current: -0.24

During the past 8 years, the highest EV-to-EBITDA of I-MAB was 47.70. The lowest was -24.83. And the median was 1.40.

IMAB's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.94 vs IMAB: -0.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-07), I-MAB's stock price is $2.15. I-MAB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.115. Therefore, I-MAB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


I-MAB EV-to-EBITDA Historical Data

The historical data trend for I-MAB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EV-to-EBITDA Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial 34.12 -8.68 2.78 3.31 2.04

I-MAB Quarterly Data
Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.24 1.37 1.56 2.04 2.18

Competitive Comparison of I-MAB's EV-to-EBITDA

For the Biotechnology subindustry, I-MAB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where I-MAB's EV-to-EBITDA falls into.


;
;

I-MAB EV-to-EBITDA Calculation

I-MAB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=10.632/-44.784
=-0.24

I-MAB's current Enterprise Value is $10.63 Mil.
I-MAB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

I-MAB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.15/-0.115
=At Loss

I-MAB's share price for today is $2.15.
I-MAB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.115.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


I-MAB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of I-MAB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).